Acutus Medical Inc. (AFIB): Price and Financial Metrics
AFIB Price/Volume Stats
| Current price | $0.70 | 52-week high | $1.96 |
| Prev. close | $0.70 | 52-week low | $0.40 |
| Day low | $0.65 | Volume | 36,200 |
| Day high | $0.72 | Avg. volume | 131,701 |
| 50-day MA | $0.61 | Dividend yield | N/A |
| 200-day MA | $0.94 | Market Cap | 20.48M |
AFIB Stock Price Chart Interactive Chart >
AFIB POWR Grades
- Growth is the dimension where AFIB ranks best; there it ranks ahead of 95.74% of US stocks.
- AFIB's strongest trending metric is Quality; it's been moving down over the last 43 days.
- AFIB's current lowest rank is in the Quality metric (where it is better than 2.49% of US stocks).
AFIB Stock Summary
- ACUTUS MEDICAL INC's market capitalization of $17,789,524 is ahead of only 8.73% of US-listed equities.
- With a one year PEG ratio of 0.73, ACUTUS MEDICAL INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 10.3% of US stocks.
- Of note is the ratio of ACUTUS MEDICAL INC's sales and general administrative expense to its total operating expenses; 99.71% of US stocks have a lower such ratio.
- Stocks with similar financial metrics, market capitalization, and price volatility to ACUTUS MEDICAL INC are AGIO, BLUE, LYEL, JANX, and PLRX.
- AFIB's SEC filings can be seen here. And to visit ACUTUS MEDICAL INC's official web site, go to www.acutusmedical.com.
AFIB Valuation Summary
- In comparison to the median Healthcare stock, AFIB's price/sales ratio is 47.37% lower, now standing at 1.
- AFIB's price/sales ratio has moved down 160.9 over the prior 38 months.
Below are key valuation metrics over time for AFIB.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AFIB | 2023-09-18 | 1.0 | 0.4 | -0.4 | -0.8 |
| AFIB | 2023-09-15 | 0.8 | 0.3 | -0.4 | -0.7 |
| AFIB | 2023-09-14 | 0.8 | 0.3 | -0.4 | -0.7 |
| AFIB | 2023-09-13 | 0.8 | 0.3 | -0.4 | -0.7 |
| AFIB | 2023-09-12 | 0.8 | 0.3 | -0.4 | -0.7 |
| AFIB | 2023-09-11 | 0.8 | 0.3 | -0.4 | -0.7 |
AFIB's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AFIB has a Quality Grade of F, ranking ahead of 1.4% of graded US stocks.
- AFIB's asset turnover comes in at 0.079 -- ranking 159th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows AFIB's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.079 | -0.743 | -0.714 |
| 2021-03-31 | 0.066 | -0.876 | -0.809 |
| 2020-12-31 | 0.060 | -0.877 | -0.878 |
AFIB Price Target
For more insight on analysts targets of AFIB, see our AFIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.67 | Average Broker Recommendation | 1.6 (Moderate Buy) |
Acutus Medical Inc. (AFIB) Company Bio
Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists. Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Its products are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.
Latest AFIB News From Around the Web
Below are the latest news stories about ACUTUS MEDICAL INC that investors may wish to consider to help them evaluate AFIB as an investment opportunity.
Acutus Medical, Inc. (NASDAQ:AFIB) Q2 2023 Earnings Call TranscriptAcutus Medical, Inc. (NASDAQ:AFIB) Q2 2023 Earnings Call Transcript August 7, 2023 Acutus Medical, Inc. misses on earnings expectations. Reported EPS is $-0.63 EPS, expectations were $0.61. Operator: Good day, and thank you for standing by, and welcome to the Acutus Medical Second Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s […] |
Q2 2023 Acutus Medical Inc Earnings CallQ2 2023 Acutus Medical Inc Earnings Call |
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue EstimatesAcutus Medical, Inc. (AFIB) delivered earnings and revenue surprises of -3.28% and 14.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Acutus Medical Reports Second Quarter 2023 Financial ResultsCARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21 |
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CARLSBAD, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on August 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in July 2023. The equity awards |
AFIB Price Returns
| 1-mo | 37.69% |
| 3-mo | -21.35% |
| 6-mo | -5.66% |
| 1-year | -19.71% |
| 3-year | -97.60% |
| 5-year | N/A |
| YTD | -39.13% |
| 2022 | -66.28% |
| 2021 | -88.16% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...